TipRanks
Advertisement
Advertisement

HK:2162 Stock Latest News

Keymed Biosciences announces orderly resignation of non-executive director
Company AnnouncementsKeymed Biosciences announces orderly resignation of non-executive director
24d ago
2162
Keymed Biosciences updates board and committee structure
PremiumCompany Announcements
Keymed Biosciences updates board and committee structure
24d ago
2162
Keymed Biosciences Signs Regional Licensing Deal for Stapokibart
PremiumCompany Announcements
Keymed Biosciences Signs Regional Licensing Deal for Stapokibart
27d ago
2162
Keymed Biosciences Turns Profitable on Surging Drug Sales and BD Windfall
PremiumCompany Announcements
Keymed Biosciences Turns Profitable on Surging Drug Sales and BD Windfall
1M ago
2162
Keymed Biosciences Plans RMB Share Issue for Shanghai Sci-Tech Board Listing
PremiumCompany Announcements
Keymed Biosciences Plans RMB Share Issue for Shanghai Sci-Tech Board Listing
1M ago
2162
Keymed’s CM512 Hits Phase II Targets and Wins Breakthrough Status for Nasal Polyp Treatment
PremiumCompany AnnouncementsKeymed’s CM512 Hits Phase II Targets and Wins Breakthrough Status for Nasal Polyp Treatment
2M ago
2162
Keymed Biosciences Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Premium
Company Announcements
Keymed Biosciences Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
2M ago
2162
Keymed’s CLDN18.2 Drug CMG901 Delivers Phase III Survival Gain in Gastric Cancer
Premium
Company Announcements
Keymed’s CLDN18.2 Drug CMG901 Delivers Phase III Survival Gain in Gastric Cancer
2M ago
2162
Keymed’s CM512 Wins China Breakthrough Status, Advances in Multiple Phase II Trials
PremiumCompany Announcements
Keymed’s CM512 Wins China Breakthrough Status, Advances in Multiple Phase II Trials
2M ago
2162
Keymed Biosciences Swings to Profit on Kangyueda Surge and Licensing Windfall
PremiumCompany Announcements
Keymed Biosciences Swings to Profit on Kangyueda Surge and Licensing Windfall
3M ago
2162
Keymed Biosciences Shareholders Approve All AGM Resolutions, Renew Capital Mandates
PremiumCompany Announcements
Keymed Biosciences Shareholders Approve All AGM Resolutions, Renew Capital Mandates
3M ago
2162
Keymed Biosciences Banks US$257 Million From Ouro Medicines Sale as Gilead-Lakefront Alliance Advances CM336
PremiumCompany Announcements
Keymed Biosciences Banks US$257 Million From Ouro Medicines Sale as Gilead-Lakefront Alliance Advances CM336
4M ago
2162
Keymed Biosciences Sets AGM to Approve Accounts, Board Changes and New Share Mandate
PremiumCompany AnnouncementsKeymed Biosciences Sets AGM to Approve Accounts, Board Changes and New Share Mandate
5M ago
2162
Keymed Biosciences Details Gain and Capital Plans From Ouro Medicines Stake Disposal
Premium
Company Announcements
Keymed Biosciences Details Gain and Capital Plans From Ouro Medicines Stake Disposal
6M ago
2162
Keymed Biosciences boosts revenue on Kangyueda push while deepening R&D pipeline
Premium
Company Announcements
Keymed Biosciences boosts revenue on Kangyueda push while deepening R&D pipeline
6M ago
2162
M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
PremiumMarket News
M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
6M ago
GSK
GILD
Keymed Biosciences to Realize Up to US$320 Million From Ouro Medicines Exit
PremiumCompany Announcements
Keymed Biosciences to Realize Up to US$320 Million From Ouro Medicines Exit
6M ago
2162
Keymed Biosciences Sets March 26 Board Meeting to Approve 2025 Results and Consider Final Dividend
PremiumCompany Announcements
Keymed Biosciences Sets March 26 Board Meeting to Approve 2025 Results and Consider Final Dividend
7M ago
2162
Keymed Gains US$45 Million Milestone as AstraZeneca Starts Phase III Trial of Core Cancer Drug
PremiumCompany Announcements
Keymed Gains US$45 Million Milestone as AstraZeneca Starts Phase III Trial of Core Cancer Drug
7M ago
2162
Keymed Biosciences’ Strategic Positioning and Stapokibart’s Market Potential in Biotech Sector
PremiumRatingsKeymed Biosciences’ Strategic Positioning and Stapokibart’s Market Potential in Biotech Sector
11M ago
Keymed Biosciences Reports Strong Revenue Growth Amid Leadership Change
Premium
Company Announcements
Keymed Biosciences Reports Strong Revenue Growth Amid Leadership Change
1y ago
2162
Keymed Biosciences Schedules Board Meeting to Review Interim Results
Premium
Company Announcements
Keymed Biosciences Schedules Board Meeting to Review Interim Results
1y ago
2162

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >